Clinical Trial Update: Safety of Nintedanib in Real World in China

View source ↗

Summary

The real-world safety study of nintedanib in China (NCT05676112) sponsored by Boehringer Ingelheim has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Fibrosis | Status: WITHDRAWN